No, Jardiance Cannot Treat Arthritis
Jardiance (empagliflozin) is not indicated for the treatment of arthritis and should not be used for this purpose. The FDA-approved indications for Jardiance are limited to improving glycemic control in type 2 diabetes, reducing cardiovascular death in patients with type 2 diabetes and established cardiovascular disease, and treating heart failure 1, 2, 3.
Why This Question Arises
The confusion likely stems from emerging preclinical research showing that SGLT2 inhibitors like empagliflozin may have anti-inflammatory effects on cartilage in laboratory settings 4, 5. However, these are experimental findings in mice and cell cultures—not evidence for clinical use in humans with arthritis.
Established Arthritis Treatment
For patients with arthritis, evidence-based treatment follows clear guidelines:
For Inflammatory Arthritis (Rheumatoid Arthritis, Psoriatic Arthritis)
- Methotrexate is the anchor drug and should be part of first-line treatment unless contraindicated 6, 7, 8
- Patients should be referred to a rheumatologist within 6 weeks of symptom onset 6
- If methotrexate fails, biologic DMARDs (TNF inhibitors, IL-6 inhibitors, JAK inhibitors) or targeted synthetic DMARDs should be initiated 7, 8
- NSAIDs provide symptomatic relief but should be used at minimum effective doses for the shortest duration 6
- Glucocorticoids can be used temporarily (<6 months) at the lowest necessary dose 6
For Osteoarthritis
The recent preclinical studies 4, 5 suggest potential mechanisms by which SGLT2 inhibitors might affect cartilage metabolism, but no clinical trials have demonstrated efficacy or safety in human osteoarthritis patients. Standard osteoarthritis management includes weight management, physical therapy, NSAIDs, and intra-articular injections—not SGLT2 inhibitors.
Important Clinical Context
If a patient with arthritis also has type 2 diabetes and cardiovascular disease or heart failure, Jardiance may be appropriate for their diabetes and cardiovascular conditions—not for arthritis treatment 1, 2, 9, 10. The 2025 ADA guidelines recommend SGLT2 inhibitors like empagliflozin for patients with type 2 diabetes who have established cardiovascular disease or are at high cardiovascular risk 2.
Key Safety Considerations for Jardiance
If prescribed for appropriate indications, be aware of:
- Genital mycotic infections (more common than with other diabetes medications) 3
- Volume depletion and hypotension risk 3
- Rare but serious: Fournier's gangrene, ketoacidosis, urinary tract infections 3
- Contraindicated with eGFR <30 mL/min/1.73 m² 1, 2
Bottom Line
Do not prescribe Jardiance for arthritis. Refer patients with arthritis to rheumatology for evidence-based DMARD therapy. If the patient coincidentally has type 2 diabetes with cardiovascular disease or heart failure, Jardiance may be appropriate for those conditions, but this is entirely separate from arthritis management. The experimental research showing cartilage effects in mice 4, 5 is interesting scientifically but does not translate to clinical practice recommendations.